{"id": "article-30294_0", "title": "Stevens-Johnson Syndrome -- Continuing Education Activity", "content": "Stevens-Johnson syndrome and toxic epidermal necrolysis are acute, rare, and potentially fatal skin reactions involving loss of skin and, in some cases, mucosal membranes accompanied by systemic symptoms. Medications are causative in over 80 percent of cases. Stevens-Johnson syndrome and toxic epidermal necrolysis are distinguished based on the extent of the detached skin surface area. This activity illustrates the evaluation and treatment of Stevens-Johnson syndrome and of toxic epidermal necrolysis and reviews the role of the interprofessional team in managing those with these conditions.", "contents": "Stevens-Johnson Syndrome -- Continuing Education Activity. Stevens-Johnson syndrome and toxic epidermal necrolysis are acute, rare, and potentially fatal skin reactions involving loss of skin and, in some cases, mucosal membranes accompanied by systemic symptoms. Medications are causative in over 80 percent of cases. Stevens-Johnson syndrome and toxic epidermal necrolysis are distinguished based on the extent of the detached skin surface area. This activity illustrates the evaluation and treatment of Stevens-Johnson syndrome and of toxic epidermal necrolysis and reviews the role of the interprofessional team in managing those with these conditions."}
{"id": "article-30294_1", "title": "Stevens-Johnson Syndrome -- Continuing Education Activity", "content": "Objectives: Describe the difference between Stevens-Johnson syndrome and toxic epidermal necrolysis. Summarize differential diagnoses of Stevens-Johnson syndrome and of toxic epidermal necrolysis. Review the treatment options for Stevens-Johnson syndrome and toxic epidermal necrolysis. Explain the role of interprofessional team members in optimizing collaboration and communication to ensure patients with Stevens-Johnson syndrome or toxic epidermal necrolysis receive high-quality care, which will lead to enhanced outcomes. Access free multiple choice questions on this topic.", "contents": "Stevens-Johnson Syndrome -- Continuing Education Activity. Objectives: Describe the difference between Stevens-Johnson syndrome and toxic epidermal necrolysis. Summarize differential diagnoses of Stevens-Johnson syndrome and of toxic epidermal necrolysis. Review the treatment options for Stevens-Johnson syndrome and toxic epidermal necrolysis. Explain the role of interprofessional team members in optimizing collaboration and communication to ensure patients with Stevens-Johnson syndrome or toxic epidermal necrolysis receive high-quality care, which will lead to enhanced outcomes. Access free multiple choice questions on this topic."}
{"id": "article-30294_2", "title": "Stevens-Johnson Syndrome -- Introduction", "content": "Previously known as Lyell syndrome, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) are variants of the same condition and are distinct from\u00a0erythema multiforme major staphylococcal scalded skin syndrome\u00ad, and other drug eruptions. [1] [2] [3]", "contents": "Stevens-Johnson Syndrome -- Introduction. Previously known as Lyell syndrome, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) are variants of the same condition and are distinct from\u00a0erythema multiforme major staphylococcal scalded skin syndrome\u00ad, and other drug eruptions. [1] [2] [3]"}
{"id": "article-30294_3", "title": "Stevens-Johnson Syndrome -- Introduction", "content": "Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis is a rare, acute, serious, and potentially fatal skin reaction in which there are sheet-like skin and mucosal loss accompanied by systemic symptoms. Medications are causative in over 80% of cases. Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis\u00a0is classified by the extent of\u00a0the detached skin surface area. Stevens-Johnson\u00a0syndrome: less than 10% body surface area Overlap\u00a0Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis: 10% to 30%\u00a0body surface area Toxic epidermal necrolysis\u00a0more than 30% body surface area", "contents": "Stevens-Johnson Syndrome -- Introduction. Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis is a rare, acute, serious, and potentially fatal skin reaction in which there are sheet-like skin and mucosal loss accompanied by systemic symptoms. Medications are causative in over 80% of cases. Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis\u00a0is classified by the extent of\u00a0the detached skin surface area. Stevens-Johnson\u00a0syndrome: less than 10% body surface area Overlap\u00a0Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis: 10% to 30%\u00a0body surface area Toxic epidermal necrolysis\u00a0more than 30% body surface area"}
{"id": "article-30294_4", "title": "Stevens-Johnson Syndrome -- Etiology", "content": "Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis\u00a0is a rare and unpredictable reaction to medication\u00a0that involves drug-specific CD8+ cytotoxic lymphocytes, the Fas-Fas ligand (FasL) pathway of apoptosis, and granule-mediated exocytosis and tumor necrosis factor-alfa (TNF\u2013alpha)/death receptor pathway. [4] [5] Current theories address the following mechanisms, among others. Granulysin, found in the cytotoxic granules, is the main cause of keratinocyte apoptosis. Fas\u2013FasL, expressed on the activated cytotoxic T cells, can also destroy keratinocytes via the production of intracellular caspases. Cytotoxic T cells exocytose perforin and granzyme B, which create channels in the target cell membrane activating the caspases. TNF\u2013alpha may cause apoptosis or protect from it. Nitrous oxide (NO) induced by TNF\u2013alpha and interferon (IFN)\u2013alpha may stimulate caspases.", "contents": "Stevens-Johnson Syndrome -- Etiology. Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis\u00a0is a rare and unpredictable reaction to medication\u00a0that involves drug-specific CD8+ cytotoxic lymphocytes, the Fas-Fas ligand (FasL) pathway of apoptosis, and granule-mediated exocytosis and tumor necrosis factor-alfa (TNF\u2013alpha)/death receptor pathway. [4] [5] Current theories address the following mechanisms, among others. Granulysin, found in the cytotoxic granules, is the main cause of keratinocyte apoptosis. Fas\u2013FasL, expressed on the activated cytotoxic T cells, can also destroy keratinocytes via the production of intracellular caspases. Cytotoxic T cells exocytose perforin and granzyme B, which create channels in the target cell membrane activating the caspases. TNF\u2013alpha may cause apoptosis or protect from it. Nitrous oxide (NO) induced by TNF\u2013alpha and interferon (IFN)\u2013alpha may stimulate caspases."}
{"id": "article-30294_5", "title": "Stevens-Johnson Syndrome -- Epidemiology", "content": "Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis\u00a0is estimated to affect two to seven per million people each year. Stevens-Johnson syndrome\u00a0is three times more common than toxic epidermal necrolysis.\u00a0Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis\u00a0can affect anyone with a genetic predisposition: any age, either sex, and all races, although it is more common in older people and women. It is much more likely to occur in people infected with the human immunodeficiency virus (HIV), with an estimated incidence of 1/1000. [6] [7] [8] Numerous medications have been reported to trigger\u00a0Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis. Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis\u00a0are rarely associated with vaccination and infections such as mycoplasma, cytomegalovirus, and dengue. The drugs that most commonly cause Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0are:", "contents": "Stevens-Johnson Syndrome -- Epidemiology. Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis\u00a0is estimated to affect two to seven per million people each year. Stevens-Johnson syndrome\u00a0is three times more common than toxic epidermal necrolysis.\u00a0Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis\u00a0can affect anyone with a genetic predisposition: any age, either sex, and all races, although it is more common in older people and women. It is much more likely to occur in people infected with the human immunodeficiency virus (HIV), with an estimated incidence of 1/1000. [6] [7] [8] Numerous medications have been reported to trigger\u00a0Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis. Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis\u00a0are rarely associated with vaccination and infections such as mycoplasma, cytomegalovirus, and dengue. The drugs that most commonly cause Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0are:"}
{"id": "article-30294_6", "title": "Stevens-Johnson Syndrome -- Epidemiology", "content": "Anticonvulsants: lamotrigine, carbamazepine, phenytoin, phenobarbitone Allopurinol, especially in doses of more than 100 mg per day Sulfonamides: cotrimoxazole, sulfasalazine Antibiotics: penicillins, cephalosporins, quinolones, minocycline Paracetamol/acetaminophen Nevirapine (non-nucleoside reverse-transcriptase inhibitor) Nonsteroidal anti-inflammatory drugs (NSAIDs) (oxicam type mainly) Contrast media", "contents": "Stevens-Johnson Syndrome -- Epidemiology. Anticonvulsants: lamotrigine, carbamazepine, phenytoin, phenobarbitone Allopurinol, especially in doses of more than 100 mg per day Sulfonamides: cotrimoxazole, sulfasalazine Antibiotics: penicillins, cephalosporins, quinolones, minocycline Paracetamol/acetaminophen Nevirapine (non-nucleoside reverse-transcriptase inhibitor) Nonsteroidal anti-inflammatory drugs (NSAIDs) (oxicam type mainly) Contrast media"}
{"id": "article-30294_7", "title": "Stevens-Johnson Syndrome -- Epidemiology", "content": "Genetic factors include human leukocyte antigen ( HLA ) allotypes that lead to an increased risk of Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0when exposed to aromatic anticonvulsants and allopurinol. Family members of a patient with Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0should be advised\u00a0that they are at risk of developing the disease and should\u00a0be cautious about taking any medications associated with the disease. [9] To date, findings have included the risk of Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0in: Han Chinese, Thai, Malaysian, and South Indian people if they carry HLA-B*1502 and take aromatic anticonvulsants. Han Chinese if they carry HLA-B*5801 and take allopurinol Europeans if they carry HLA-B*5701 and take abacavir, or\u00a0if they carry HLA-A*3101 and take carbamazepine.", "contents": "Stevens-Johnson Syndrome -- Epidemiology. Genetic factors include human leukocyte antigen ( HLA ) allotypes that lead to an increased risk of Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0when exposed to aromatic anticonvulsants and allopurinol. Family members of a patient with Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0should be advised\u00a0that they are at risk of developing the disease and should\u00a0be cautious about taking any medications associated with the disease. [9] To date, findings have included the risk of Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0in: Han Chinese, Thai, Malaysian, and South Indian people if they carry HLA-B*1502 and take aromatic anticonvulsants. Han Chinese if they carry HLA-B*5801 and take allopurinol Europeans if they carry HLA-B*5701 and take abacavir, or\u00a0if they carry HLA-A*3101 and take carbamazepine."}
{"id": "article-30294_8", "title": "Stevens-Johnson Syndrome -- Pathophysiology", "content": "The initial step for Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0may be interaction/binding of a drug-associated antigen or metabolite with the major histocompatibility complex (MHC) type 1 or cellular peptide to form an immunogenic compound. The exact mechanism is speculative. [10] Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0is T\u2013cell-mediated. CD8+ cells are present in blister fluid and may induce keratinocyte apoptosis. Other cells of the innate immune system play a role. CD40 ligand cells are also present and may induce the release of TNF\u2013alpha, nitrous oxide, interleukin 8 (IL-8), and cell adhesion antibodies. TNF\u2013alpha also induces apoptosis. Both Th1 and Th2 cytokines are present. Other cells implicated in Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0include macrophages, neutrophils, and natural killer (NK) cells.", "contents": "Stevens-Johnson Syndrome -- Pathophysiology. The initial step for Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0may be interaction/binding of a drug-associated antigen or metabolite with the major histocompatibility complex (MHC) type 1 or cellular peptide to form an immunogenic compound. The exact mechanism is speculative. [10] Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0is T\u2013cell-mediated. CD8+ cells are present in blister fluid and may induce keratinocyte apoptosis. Other cells of the innate immune system play a role. CD40 ligand cells are also present and may induce the release of TNF\u2013alpha, nitrous oxide, interleukin 8 (IL-8), and cell adhesion antibodies. TNF\u2013alpha also induces apoptosis. Both Th1 and Th2 cytokines are present. Other cells implicated in Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0include macrophages, neutrophils, and natural killer (NK) cells."}
{"id": "article-30294_9", "title": "Stevens-Johnson Syndrome -- Pathophysiology", "content": "The pharmacologic interaction of drugs with the immune system could result in binding of the responsible drug to MHC-1 and the T cell receptor. An alternative theory is a pro-hapten concept, in which drug metabolites become immunogenic and stimulate the immune system.", "contents": "Stevens-Johnson Syndrome -- Pathophysiology. The pharmacologic interaction of drugs with the immune system could result in binding of the responsible drug to MHC-1 and the T cell receptor. An alternative theory is a pro-hapten concept, in which drug metabolites become immunogenic and stimulate the immune system."}
{"id": "article-30294_10", "title": "Stevens-Johnson Syndrome -- Histopathology", "content": "Histology of the skin reveals\u00a0necrosis of keratinocytes, epidermal (or epithelial) necrosis, and mild lymphocytic dermal infiltration. Direct immune fluorescence is negative.", "contents": "Stevens-Johnson Syndrome -- Histopathology. Histology of the skin reveals\u00a0necrosis of keratinocytes, epidermal (or epithelial) necrosis, and mild lymphocytic dermal infiltration. Direct immune fluorescence is negative."}
{"id": "article-30294_11", "title": "Stevens-Johnson Syndrome -- Toxicokinetics", "content": "The drugs that precipitate Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0tend to\u00a0have long half-lives and are nearly always taken systemically. Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0can\u00a0develop within a few days to eight weeks after starting a\u00a0new drug. A subsequent exposure can result in symptoms within a few hours.", "contents": "Stevens-Johnson Syndrome -- Toxicokinetics. The drugs that precipitate Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0tend to\u00a0have long half-lives and are nearly always taken systemically. Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0can\u00a0develop within a few days to eight weeks after starting a\u00a0new drug. A subsequent exposure can result in symptoms within a few hours."}
{"id": "article-30294_12", "title": "Stevens-Johnson Syndrome -- History and Physical", "content": "The illness\u00a0begins with nonspecific symptoms such as fever and malaise, upper respiratory tract symptoms such as a cough, rhinitis, sore eyes, and myalgia. Over the next three to four days,\u00a0a blistering rash and erosions\u00a0appear on the face, trunk, limbs, and mucosal surfaces. Erythematous, targetoid, annular, or purpuric macules Flaccid bullae Large painful erosions Nikolsky-positive (lateral pressure on the skin results in shedding of the epidermis)", "contents": "Stevens-Johnson Syndrome -- History and Physical. The illness\u00a0begins with nonspecific symptoms such as fever and malaise, upper respiratory tract symptoms such as a cough, rhinitis, sore eyes, and myalgia. Over the next three to four days,\u00a0a blistering rash and erosions\u00a0appear on the face, trunk, limbs, and mucosal surfaces. Erythematous, targetoid, annular, or purpuric macules Flaccid bullae Large painful erosions Nikolsky-positive (lateral pressure on the skin results in shedding of the epidermis)"}
{"id": "article-30294_13", "title": "Stevens-Johnson Syndrome -- History and Physical", "content": "Early on, toxic epidermal necrolysis\u00a0displays widespread tender erythroderma and erosions (with or without targetoid rash), whereas Stevens-Johnson syndrome\u00a0is characterized more by targetoid rash, with fewer areas of denudation.", "contents": "Stevens-Johnson Syndrome -- History and Physical. Early on, toxic epidermal necrolysis\u00a0displays widespread tender erythroderma and erosions (with or without targetoid rash), whereas Stevens-Johnson syndrome\u00a0is characterized more by targetoid rash, with fewer areas of denudation."}
{"id": "article-30294_14", "title": "Stevens-Johnson Syndrome -- History and Physical", "content": "Mucosal ulceration and erosions can involve lips, mouth, pharynx, esophagus and gastrointestinal tract, eyes, genitals,\u00a0upper respiratory tract. About half of patients have involvement of three mucosal sites. The patient is very\u00a0ill, anxious, and in pain. Liver, kidneys, lungs, bone marrow, and joints may be affected by Stevens-Johnson syndrome/toxic epidermal necrolysis. Typical symptoms include: Fever, malaise, headache, anorexia, pharyngitis\u00ad Symptoms due to acute dysfunction of ocular, pulmonary, cardiovascular, gastrointestinal, renal, and hematological systems.", "contents": "Stevens-Johnson Syndrome -- History and Physical. Mucosal ulceration and erosions can involve lips, mouth, pharynx, esophagus and gastrointestinal tract, eyes, genitals,\u00a0upper respiratory tract. About half of patients have involvement of three mucosal sites. The patient is very\u00a0ill, anxious, and in pain. Liver, kidneys, lungs, bone marrow, and joints may be affected by Stevens-Johnson syndrome/toxic epidermal necrolysis. Typical symptoms include: Fever, malaise, headache, anorexia, pharyngitis\u00ad Symptoms due to acute dysfunction of ocular, pulmonary, cardiovascular, gastrointestinal, renal, and hematological systems."}
{"id": "article-30294_15", "title": "Stevens-Johnson Syndrome -- History and Physical", "content": "Features may overlap with other severe cutaneous adverse reactions (SCAR), such as acute generalized exanthematous pustulosis (causing subcorneal pustules) and drug hypersensitivity syndrome (causing a morbilliform eruption and involving other organs).", "contents": "Stevens-Johnson Syndrome -- History and Physical. Features may overlap with other severe cutaneous adverse reactions (SCAR), such as acute generalized exanthematous pustulosis (causing subcorneal pustules) and drug hypersensitivity syndrome (causing a morbilliform eruption and involving other organs)."}
{"id": "article-30294_16", "title": "Stevens-Johnson Syndrome -- Evaluation", "content": "Investigations may include: Urgent frozen sections of skin biopsy: full-thickness skin necrosis Direct immune fluorescence: negative Complete blood count (CBC): anemia, lymphopenia, neutropenia, eosinophilia, atypical lymphocytosis Liver function tests (LFT): elevated transaminases, hypoalbuminemia Renal function: microalbuminuria, renal tubular enzymes in urine, reduced glomerular filtration, rising creatinine and urea, hyponatremia Pulmonary function: bronchial mucosal sloughing on bronchoscopy, interstitial infiltrates on chest x-ray Cardiac function: abnormal ECG and imaging. The severity of Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0is assessed using SCORTEN. One point is scored for each of the following seven\u00a0criteria at admission.", "contents": "Stevens-Johnson Syndrome -- Evaluation. Investigations may include: Urgent frozen sections of skin biopsy: full-thickness skin necrosis Direct immune fluorescence: negative Complete blood count (CBC): anemia, lymphopenia, neutropenia, eosinophilia, atypical lymphocytosis Liver function tests (LFT): elevated transaminases, hypoalbuminemia Renal function: microalbuminuria, renal tubular enzymes in urine, reduced glomerular filtration, rising creatinine and urea, hyponatremia Pulmonary function: bronchial mucosal sloughing on bronchoscopy, interstitial infiltrates on chest x-ray Cardiac function: abnormal ECG and imaging. The severity of Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0is assessed using SCORTEN. One point is scored for each of the following seven\u00a0criteria at admission."}
{"id": "article-30294_17", "title": "Stevens-Johnson Syndrome -- Evaluation", "content": "Age \u00a0older than 40 years Presence of a malignancy Heart rate of more than 120 bpm Initial percentage of epidermal detachment greater than 10% Serum urea level greater than 10 mmol/L Serum glucose level greater than 14 mmol/L Serum bicarbonate level less than 20 mmol/L", "contents": "Stevens-Johnson Syndrome -- Evaluation. Age \u00a0older than 40 years Presence of a malignancy Heart rate of more than 120 bpm Initial percentage of epidermal detachment greater than 10% Serum urea level greater than 10 mmol/L Serum glucose level greater than 14 mmol/L Serum bicarbonate level less than 20 mmol/L"}
{"id": "article-30294_18", "title": "Stevens-Johnson Syndrome -- Evaluation", "content": "The risk of dying from Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0depends on the score.\u00a0The mortality rate is more than 40 times higher in those with bicarbonate levels less than 20 mmol/L compared with those with higher levels. \u00a0A SCORTEN ranges with their associated mortality (in\u00a0%) are\u00a0as follows: score 0-1 (3.2%), score 2 (12.1%), score 3 (35.3%), score 4 (58.3%), and score 5 (>90%). [11] [12] In patients on multiple drugs known to cause Stevens-Johnson syndrome/toxic epidermal necrolysis, the algorithm ALDEN has been developed to determine the likely cause.", "contents": "Stevens-Johnson Syndrome -- Evaluation. The risk of dying from Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0depends on the score.\u00a0The mortality rate is more than 40 times higher in those with bicarbonate levels less than 20 mmol/L compared with those with higher levels. \u00a0A SCORTEN ranges with their associated mortality (in\u00a0%) are\u00a0as follows: score 0-1 (3.2%), score 2 (12.1%), score 3 (35.3%), score 4 (58.3%), and score 5 (>90%). [11] [12] In patients on multiple drugs known to cause Stevens-Johnson syndrome/toxic epidermal necrolysis, the algorithm ALDEN has been developed to determine the likely cause."}
{"id": "article-30294_19", "title": "Stevens-Johnson Syndrome -- Evaluation", "content": "The period between drug intake and the onset of reaction (index day): 5 to 28 days (score of 3), 29 to 56 days (2), 1 to 4 days (1), more than 56 days (\u20131), index day (\u20133) for the first episode; \u00a01 to 4 days (score of 3), 5 to 56 days (1) for a subsequent episode Presence of drug on index day or within five times elimination half-life: stopped (1), unknown (0), stopped earlier (\u20131), continued beyond index day (\u20132) Previous history of adverse reaction to the same drug: Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0(4), Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0to a similar drug (2), other reaction to same or similar drug (1), none (0), previous use without reaction (\u20132) The notoriety of the drug, according to SCAR study: high risk (3), lower risk (2), possible\u00a0risk (1), under surveillance or new drug (0), no evidence of association (\u20131) Other possible\u00a0cause: infection (\u20131), another drug that high risk (\u20131 for each other drug)", "contents": "Stevens-Johnson Syndrome -- Evaluation. The period between drug intake and the onset of reaction (index day): 5 to 28 days (score of 3), 29 to 56 days (2), 1 to 4 days (1), more than 56 days (\u20131), index day (\u20133) for the first episode; \u00a01 to 4 days (score of 3), 5 to 56 days (1) for a subsequent episode Presence of drug on index day or within five times elimination half-life: stopped (1), unknown (0), stopped earlier (\u20131), continued beyond index day (\u20132) Previous history of adverse reaction to the same drug: Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0(4), Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0to a similar drug (2), other reaction to same or similar drug (1), none (0), previous use without reaction (\u20132) The notoriety of the drug, according to SCAR study: high risk (3), lower risk (2), possible\u00a0risk (1), under surveillance or new drug (0), no evidence of association (\u20131) Other possible\u00a0cause: infection (\u20131), another drug that high risk (\u20131 for each other drug)"}
{"id": "article-30294_20", "title": "Stevens-Johnson Syndrome -- Treatment / Management", "content": "Patients should undergo interprofessional assessment in a specialized hospital environment. [13] [14] [15] Intensivist Dermatologist Plastic surgery or burns specialist Ophthalmologist Gynecologist Urologist\u00ad Respiratory physician Physical therapist Nutritionist Care of a patient with Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0requires supportive care [16] , including: Cessation of the suspected causative drug(s) Hospital admission: preferably to an intensive care and/or burn unit Fluid replacement (crystalloid) Nutritional assessment: may require nasogastric tube feeding Temperature\u00a0control: warm environment, emergency blanket Pain relief Supplemental oxygen and, in some cases, intubation with mechanical ventilation Sterile/aseptic handling", "contents": "Stevens-Johnson Syndrome -- Treatment / Management. Patients should undergo interprofessional assessment in a specialized hospital environment. [13] [14] [15] Intensivist Dermatologist Plastic surgery or burns specialist Ophthalmologist Gynecologist Urologist\u00ad Respiratory physician Physical therapist Nutritionist Care of a patient with Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0requires supportive care [16] , including: Cessation of the suspected causative drug(s) Hospital admission: preferably to an intensive care and/or burn unit Fluid replacement (crystalloid) Nutritional assessment: may require nasogastric tube feeding Temperature\u00a0control: warm environment, emergency blanket Pain relief Supplemental oxygen and, in some cases, intubation with mechanical ventilation Sterile/aseptic handling"}
{"id": "article-30294_21", "title": "Stevens-Johnson Syndrome -- Treatment / Management", "content": "Skincare requires daily examination of skin and mucosal surfaces for infection, non-adherent dressings, and avoidance of trauma to the skin. Mucosal surfaces require careful cleansing\u00a0and\u00a0topical anesthetics. Gentle removal of necrotic skin/mucosal tissue Culture of skin lesions, axillae, and groins every two days Antibiotics may be required for secondary infection but are best avoided prophylactically.", "contents": "Stevens-Johnson Syndrome -- Treatment / Management. Skincare requires daily examination of skin and mucosal surfaces for infection, non-adherent dressings, and avoidance of trauma to the skin. Mucosal surfaces require careful cleansing\u00a0and\u00a0topical anesthetics. Gentle removal of necrotic skin/mucosal tissue Culture of skin lesions, axillae, and groins every two days Antibiotics may be required for secondary infection but are best avoided prophylactically."}
{"id": "article-30294_22", "title": "Stevens-Johnson Syndrome -- Treatment / Management", "content": "It is unknown whether\u00a0systemic corticosteroids are\u00a0beneficial, but they are often prescribed in high doses for the first three to five days of admission. Granulocyte colony-stimulating factor (G-CSF) may be of benefit in patients with severe neutropenia. Other drugs reported effective include systemic corticosteroids, ciclosporin, TNF-alpha inhibitors [17] , N-acetylcysteine, and intravenous immunoglobulins. Their role remains controversial.", "contents": "Stevens-Johnson Syndrome -- Treatment / Management. It is unknown whether\u00a0systemic corticosteroids are\u00a0beneficial, but they are often prescribed in high doses for the first three to five days of admission. Granulocyte colony-stimulating factor (G-CSF) may be of benefit in patients with severe neutropenia. Other drugs reported effective include systemic corticosteroids, ciclosporin, TNF-alpha inhibitors [17] , N-acetylcysteine, and intravenous immunoglobulins. Their role remains controversial."}
{"id": "article-30294_23", "title": "Stevens-Johnson Syndrome -- Differential Diagnosis", "content": "Other acute exfoliative conditions that may need consideration include: Other severe cutaneous adverse\u00a0reactions (SCAR) to drugs, such as drug hypersensitivity syndrome (DHS), acute generalized exanthematous pustulosis (AGEP) Other forms of drug eruption Erythema multiforme (EM) major Staphylococcal scalded skin syndrome Pemphigus vulgaris and pemphigus foliaceus Acute graft versus host disease. [18]", "contents": "Stevens-Johnson Syndrome -- Differential Diagnosis. Other acute exfoliative conditions that may need consideration include: Other severe cutaneous adverse\u00a0reactions (SCAR) to drugs, such as drug hypersensitivity syndrome (DHS), acute generalized exanthematous pustulosis (AGEP) Other forms of drug eruption Erythema multiforme (EM) major Staphylococcal scalded skin syndrome Pemphigus vulgaris and pemphigus foliaceus Acute graft versus host disease. [18]"}
{"id": "article-30294_24", "title": "Stevens-Johnson Syndrome -- Prognosis", "content": "Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis is potentially very serious with high mortality, predicted by the extent and severity at presentation (see SCORTEN and ALDEN above). Mean adjusted\u00a0mortality reported for the Nationwide Inpatient Sample 2009-2012\u00a0(US) was 4.8% for SJS, 19.4% for SJS/TEN overlap, and 14.8% for TEN. [19]", "contents": "Stevens-Johnson Syndrome -- Prognosis. Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis is potentially very serious with high mortality, predicted by the extent and severity at presentation (see SCORTEN and ALDEN above). Mean adjusted\u00a0mortality reported for the Nationwide Inpatient Sample 2009-2012\u00a0(US) was 4.8% for SJS, 19.4% for SJS/TEN overlap, and 14.8% for TEN. [19]"}
{"id": "article-30294_25", "title": "Stevens-Johnson Syndrome -- Prognosis", "content": "In\u00a0Cr\u00e9teil, France, 66 of 361 patients diagnosed with Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis\u00a0died (18%):\u00a02% with SJS,\u00a012% with SJS/TEN overlap, and\u00a026% with TEN. [20] There has been a trend towards improved mortality in recent years, attributed mainly to better supportive care than in earlier decades.", "contents": "Stevens-Johnson Syndrome -- Prognosis. In\u00a0Cr\u00e9teil, France, 66 of 361 patients diagnosed with Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis\u00a0died (18%):\u00a02% with SJS,\u00a012% with SJS/TEN overlap, and\u00a026% with TEN. [20] There has been a trend towards improved mortality in recent years, attributed mainly to better supportive care than in earlier decades."}
{"id": "article-30294_26", "title": "Stevens-Johnson Syndrome -- Complications", "content": "In the acute phase, sepsis is the most common\u00a0serious risk of Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis. Organ failure may occur,\u00a0including pulmonary, hepatic, and renal systems.", "contents": "Stevens-Johnson Syndrome -- Complications. In the acute phase, sepsis is the most common\u00a0serious risk of Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis. Organ failure may occur,\u00a0including pulmonary, hepatic, and renal systems."}
{"id": "article-30294_27", "title": "Stevens-Johnson Syndrome -- Complications", "content": "The most common long-term complications of Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis are ocular (including blindness), cutaneous (pigmentary changes and scarring),\u00a0and renal. Mucosal involvement with blisters\u00a0and erosions\u00a0can lead to strictures and scarring. [21]", "contents": "Stevens-Johnson Syndrome -- Complications. The most common long-term complications of Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis are ocular (including blindness), cutaneous (pigmentary changes and scarring),\u00a0and renal. Mucosal involvement with blisters\u00a0and erosions\u00a0can lead to strictures and scarring. [21]"}
{"id": "article-30294_28", "title": "Stevens-Johnson Syndrome -- Consultations", "content": "The care of patients with\u00a0Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis is multidisciplinary. Patients\u00a0with blistering involving greater than 10% of the skin surface are usually admitted to intensive care units or burns units for supportive care.", "contents": "Stevens-Johnson Syndrome -- Consultations. The care of patients with\u00a0Stevens-Johnson\u00a0syndrome/toxic epidermal necrolysis is multidisciplinary. Patients\u00a0with blistering involving greater than 10% of the skin surface are usually admitted to intensive care units or burns units for supportive care."}
{"id": "article-30294_29", "title": "Stevens-Johnson Syndrome -- Pearls and Other Issues", "content": "Death is mainly due to sepsis and multiorgan failure. Contributing causes are: Gastrointestinal bleeding Pulmonary embolism Myocardial infarction and pulmonary edema", "contents": "Stevens-Johnson Syndrome -- Pearls and Other Issues. Death is mainly due to sepsis and multiorgan failure. Contributing causes are: Gastrointestinal bleeding Pulmonary embolism Myocardial infarction and pulmonary edema"}
{"id": "article-30294_30", "title": "Stevens-Johnson Syndrome -- Pearls and Other Issues", "content": "People who have survived Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0must avoid the causative drug or structurally related medicines as Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0may recur. Cross-reactions can occur between: Anticonvulsants carbamazepine, phenytoin, lamotrigine and phenobarbital Beta-lactam antibiotics penicillin, cephalosporin, and carbapenem Nonsteroidal anti-inflammatory drugs Sulfonamides sulfamethoxazole, sulfadiazine, sulfapyridine Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0survivors may have scarring. Severe consequences can include:", "contents": "Stevens-Johnson Syndrome -- Pearls and Other Issues. People who have survived Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0must avoid the causative drug or structurally related medicines as Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0may recur. Cross-reactions can occur between: Anticonvulsants carbamazepine, phenytoin, lamotrigine and phenobarbital Beta-lactam antibiotics penicillin, cephalosporin, and carbapenem Nonsteroidal anti-inflammatory drugs Sulfonamides sulfamethoxazole, sulfadiazine, sulfapyridine Stevens-Johnson syndrome/toxic epidermal necrolysis\u00a0survivors may have scarring. Severe consequences can include:"}
{"id": "article-30294_31", "title": "Stevens-Johnson Syndrome -- Pearls and Other Issues", "content": "Ocular sequelae: dry eye, photophobia, pain, symblepharon, corneal scarring or neovascularization, trichiasis, reduced visual acuity, and blindness Cutaneous scarring, depigmentation, development of new melanocytic nevi, and pruritus Nail dystrophy, onycholysis, and loss of nails (this may recover over time) Diffuse scalp hair thinning Oral complications: discomfort, dry mouth, periodontal disease, gingival inflammation, synechiae Esophageal strictures Vulvovaginal stenosis or occlusion in females and phimosis in males Persistent pulmonary disease: bronchitis, bronchiectasis, bronchiolitis obliterans, organizing pneumonia, respiratory tract obstruction", "contents": "Stevens-Johnson Syndrome -- Pearls and Other Issues. Ocular sequelae: dry eye, photophobia, pain, symblepharon, corneal scarring or neovascularization, trichiasis, reduced visual acuity, and blindness Cutaneous scarring, depigmentation, development of new melanocytic nevi, and pruritus Nail dystrophy, onycholysis, and loss of nails (this may recover over time) Diffuse scalp hair thinning Oral complications: discomfort, dry mouth, periodontal disease, gingival inflammation, synechiae Esophageal strictures Vulvovaginal stenosis or occlusion in females and phimosis in males Persistent pulmonary disease: bronchitis, bronchiectasis, bronchiolitis obliterans, organizing pneumonia, respiratory tract obstruction"}
{"id": "article-30294_32", "title": "Stevens-Johnson Syndrome -- Enhancing Healthcare Team Outcomes", "content": "The management of SJS is interprofessional. A number of specialists are usually involved in the care of these patients, including a dermatologist, intensivist, ophthalmologist, pulmonologist, nephrologist, plastic surgeon, and gastroenterologist, functioning as an interprofessional team. The acute care of these patients is provided by wound care. The pharmacist must also closely assess the medications that the patient is receiving to prevent exacerbation of the disorder or determine if any of the patient's medications could be the trigger for the condition. Even after treatment, these patients may have severe cosmetic deficits and may require mental health counseling. If the lesions occur across joints, the patient may benefit from physical therapy to restore function and muscle strength. The patient has to be educated on the use of ocular lubricants because of the sicca-like syndrome. Many patients do\u00a0lose weight after suffering a severe reaction and should be referred to a dietitian. Following discharge, the patients need long-term follow-up to ensure that there are no functional deficits, including vision loss. Once a patient has suffered an SJS, it is highly recommended that the patient wear a warning bracelet indicating the toxic agent or allergen. [22] [16] [Level 5]", "contents": "Stevens-Johnson Syndrome -- Enhancing Healthcare Team Outcomes. The management of SJS is interprofessional. A number of specialists are usually involved in the care of these patients, including a dermatologist, intensivist, ophthalmologist, pulmonologist, nephrologist, plastic surgeon, and gastroenterologist, functioning as an interprofessional team. The acute care of these patients is provided by wound care. The pharmacist must also closely assess the medications that the patient is receiving to prevent exacerbation of the disorder or determine if any of the patient's medications could be the trigger for the condition. Even after treatment, these patients may have severe cosmetic deficits and may require mental health counseling. If the lesions occur across joints, the patient may benefit from physical therapy to restore function and muscle strength. The patient has to be educated on the use of ocular lubricants because of the sicca-like syndrome. Many patients do\u00a0lose weight after suffering a severe reaction and should be referred to a dietitian. Following discharge, the patients need long-term follow-up to ensure that there are no functional deficits, including vision loss. Once a patient has suffered an SJS, it is highly recommended that the patient wear a warning bracelet indicating the toxic agent or allergen. [22] [16] [Level 5]"}
{"id": "article-30294_33", "title": "Stevens-Johnson Syndrome -- Enhancing Healthcare Team Outcomes -- Outcomes", "content": "The outcomes of patients with SJS depend on the extent and severity of skin involvement. For those with a mild eruption, the lesions usually heal in 12\u00a0to 16 weeks. Mild scarring may occur, but there is usually no functional loss unless the eyes and other mucous membranes are involved. When the involved skin area is more than 20%, mortality rates of 1 to 27% have been reported. The presence of concomitant bacterial infection can increase mortality rates. Factors that adversely affect the outcome include advanced age, leucopenia, presence of a malignancy, renal dysfunction, hyperglycemia, and more than 10% BSA involvement. Survivors of SJS may develop inverted eyelids, sicca-like syndrome, visual loss, and corneal neovascularization, but n interprofessional approach will lead to better outcomes. [23] [24] [Level 5]", "contents": "Stevens-Johnson Syndrome -- Enhancing Healthcare Team Outcomes -- Outcomes. The outcomes of patients with SJS depend on the extent and severity of skin involvement. For those with a mild eruption, the lesions usually heal in 12\u00a0to 16 weeks. Mild scarring may occur, but there is usually no functional loss unless the eyes and other mucous membranes are involved. When the involved skin area is more than 20%, mortality rates of 1 to 27% have been reported. The presence of concomitant bacterial infection can increase mortality rates. Factors that adversely affect the outcome include advanced age, leucopenia, presence of a malignancy, renal dysfunction, hyperglycemia, and more than 10% BSA involvement. Survivors of SJS may develop inverted eyelids, sicca-like syndrome, visual loss, and corneal neovascularization, but n interprofessional approach will lead to better outcomes. [23] [24] [Level 5]"}
{"id": "article-30294_34", "title": "Stevens-Johnson Syndrome -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Stevens-Johnson Syndrome -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}